[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinal-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinal-diseases":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,70,98,131,160,180,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100641277","morpho-functional-evaluation-of-the-retina-and-choroid-using-multimodal-imaging-in-healthy-subjects-and-patients-with-retino-choroidal-diseases-100641277",false,"NCT07615699","Morpho-functional Evaluation of the Retina and Choroid Using Multimodal Imaging in Healthy Subjects and Patients With Retino-choroidal Diseases","Valutazione Morfo-funzionale Della Retina e Della Coroide Mediante Imaging Multimodale in Soggetti Sani e in Pazienti Con Patologie Retino-coroideali","RET 05-26","Inclusion Criteria:\n\n* freely given informed consent acquired prior to the start of the study.\n* Participant's capacity to understand the informed consent and study procedures.\n* Age ≥ 6 years (with parental\u002Fguardian consent for minors).\n* Patients affected by any retino-choroidal disease.\n* Healthy subjects showing no retino-choroidal pathology.\n\nExclusion Criteria:\n\n* Patient unable and\u002For unwilling to cooperate.\n* Presence of media opacities (dioptric media) that prevent image acquisition or significantly reduce the quality of the obtained images.",true,"ALL","6 Years",{"count":21,"type":22},125,"ESTIMATED","OBSERVATIONAL","The purpose of this prospective, longitudinal, single-center observational study is to identify, describe, and measure the morpho-functional characteristics and modifications of the retina and choroid using advanced multimodal imaging techniques. The study will evaluate patients affected by retino-choroidal diseases and compare them with healthy controls over a 5-year follow-up period to track the evolution of these parameters over time.",[26,27,28],"Retinal Diseases","Choroidal Diseases","Healthy Subjects","NOT_YET_RECRUITING","2026-05-28",{"date":32,"type":33},"2026-05-29","ACTUAL",{"date":35,"type":22},"2026-07-01",{"date":37,"type":22},"2033-06-01",{"name":39,"class":40},"Fondazione G.B. Bietti, IRCCS","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":17,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100635660","defining-retinal-structures-using-hyperspectral-retinal-imaging-100635660","NCT07555574","Defining Retinal Structures Using Hyperspectral Retinal Imaging","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Able to provide informed consent\n* Willing and able to attend a study visit at the Centre for Eye Research Australia\n* Participants with diagnosed retinal or optic nerve disease (e.g., diabetic retinopathy, glaucoma, age-related macular degeneration)\n* Age- and sex-matched healthy control participants without known retinal or optic nerve disease\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)\n* Known contraindication to pharmacological pupil dilation\n* History of narrow anterior chamber angle or risk of angle closure glaucoma where dilation is considered unsafe\n* Any condition that, in the investigator's opinion, would compromise participant safety or image quality","18 Years",{"count":49,"type":22},1000,"INTERVENTIONAL",[52],"NA","This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography.\n\nApproximately 1000 participants will undergo multi-modal ophthalmic imaging in Melbourne, Australia, including hyperspectral imaging, OCT, fundus photography, and related tests. The study aims to compare hyperspectral imaging with standard imaging methods and assess its ability to identify retinal biomarkers associated with diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.",[55,56,57,26,58],"Age-Related Macular Degeneration","Diabetic Retinopathy","Glaucoma","Healthy Volunteers","RECRUITING","2026-04-21",{"date":62,"type":33},"2026-04-29",{"date":64,"type":33},"2025-01-01",{"date":66,"type":22},"2028-12-30",{"name":68,"class":40},"Center for Eye Research Australia",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":50,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":69},"100594843","4d-duke-microscope-integrated-optical-coherence-tomography-in-a-zeiss-artevo-800-100594843","NCT07024719","4D Duke Microscope Integrated Optical Coherence Tomography in a Zeiss Artevo 800","First Use of Duke 4D Microscope Integrated OCT (MIOCT) Integrated Into Zeiss Artevo 800 Ophthalmic Surgical Microscope in the Operating Room","4D MIOCT","Inclusion Criteria:\n\n* Adult participants 18 years of age and older\n* Patients undergoing surgery for ocular disease\n* Adults able and willing to give informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients with any ocular disease that restricts the ability to perform OCT scanning",{"count":79,"type":22},5,[52],"The study team will conduct the first in-human pilot studies using 4D MIOCT for imaging in the operating room. Building on the earlier integration and wet-lab validations, the researchers will assess the system's ease of use, safety, and visualization of intended structures during various anterior and posterior segment ophthalmic procedures.",[83,26,84],"Corneal Diseases","Ocular Diseases",[86,87,88],"Microscope integrated OCT","intraoperative OCT","optical coherence tomography (OCT)","2026-01-14",{"date":91,"type":33},"2026-01-16",{"date":93,"type":33},"2025-07-24",{"date":95,"type":22},"2026-10",{"name":97,"class":40},"Duke University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":18,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":50,"phases":108,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":69},"100606371","phase-2-sglt2-inhibitors-in-geographic-atrophy-100606371","NCT07174687","SGLT2 Inhibitors in Geographic Atrophy","Efficacy of Dapagliflozin in the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration","Inclusion Criteria:\n\n1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol\n2. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures\n3. Participant is male or, if female, participant is surgically sterilized or amenorrheic for at least one year\n4. ≥50 years old\n5. Evidence of dry advanced AMD with the presence of non-foveal Geographic Atrophy (GA)\n\n   1. The geographic atrophy must not involve the center point of the fovea.\n   2. Total area of geographic atrophy must be between 2.5 mm2 and 17.5 mm2 (1 - 4 disc areas, respectively).\n   3. If the geographic atrophy consists of multiple lesions, at least one lesion must have an area of ≥1.25 mm² (equivalent to 0.5 disc areas).\n6. BCVA between 20\u002F25 and 20\u002F320\n7. Must be treatment-naïve for AMD, except for oral supplements\n\nExclusion Criteria:\n\n1. Prior investigational drug use within 60 days\n2. Use of other SGLT2 inhibitors\n3. History of symptomatic hypotension or symptomatic hypotension (symptoms of hypotension + SBP \\\u003C 90mmHg) at baseline\n4. Type I and Type II Diabetes Mellitus\n5. End stage renal disease or estimated glomerular filtration rate less than 25 mL\u002Fmin\u002F1.73 m2 per MDRD calculation\n6. History of heart failure\n7. History of a serious hypersensitivity reaction to dapagliflozin or any of the excipients in FARXIGA\n8. Other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the study instructions or follow-up procedures\n9. Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins or mineral\n10. Any intraocular surgery or thermal laser within 3 months of date of randomization\n11. Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks\n12. Any prior thermal laser in the macular region, regardless of indication (self-report)\n13. Any evidence of choroidal neovascularization in study eye\n14. Enrollment in another interventional trial during the trial period","50 Years",{"count":107,"type":22},70,[109],"PHASE2","AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.",[112,26,113,114,115],"Retinal Degeneration","Eye Diseases","Geographic Atrophy","Pathological Conditions, Anatomical",[117,118,119,120,121],"Geographic Atrophy (GA)","Age-related Macular Degeneration","AMD","SGLT2","Dapagliflozin","2025-12-16",{"date":124,"type":33},"2025-12-18",{"date":126,"type":33},"2025-12-02",{"date":128,"type":22},"2028-06",{"name":130,"class":40},"Washington University School of Medicine",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":17,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":141,"conditions":142,"keywords":147,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":69},"100241590","discover-study-microscope-integrated-intraoperative-oct-study-100241590","NCT02423213","DISCOVER Study: Microscope-integrated Intraoperative OCT Study","Determination of Feasibility of Intraoperative Spectral Domain Microscope Combined\u002FIntegrated OCT Visualization During En Face Retinal and Ophthalmic Surgery: DISCOVER Study","DISCOVER","Inclusion Criteria:\n\n* The study population includes any patient requiring ophthalmic surgery\n\nExclusion Criteria:\n\n* Under the age of 18 years.\n* Cognitive\u002FMentally impaired or unable to provide consent",{"count":140,"type":22},3000,"Optical coherence tomography (OCT )provides high resolution information regarding the anatomic structure of the tissues of the eye in a cross-sectional and 3 dimensional view. Much of this information is not able to be visualized by a clinician. Utilizing this information during surgery will allow for the ophthalmic surgeons to better understand how surgical procedures impact the anatomic structure of the eye.\n\nIn this study an OCT device that has been built into the microscope (rather than mounted on the side or held in the surgeon's hand) and will be utilized to take images at various milestones during surgery to assess feasibility and potential utility of this technology. Since it is built into the microscope, there are potential significant advantages over a separate system including increased efficiency, improved working distance, and the ability to visualize tissue-instrument interactions.",[26,143,144,145,146],"Fuchs Endothelial Dystrophy","Macular Hole","Epiretinal Membrane","Retinal Detachment",[148,149,150],"OCT","image-guided surgery","ophthalmic surgery","2025-06-23",{"date":153,"type":33},"2025-06-26",{"date":155,"type":4},"2014-01",{"date":157,"type":22},"2027-01",{"name":159,"class":40},"The Cleveland Clinic",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":17,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":50,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":69},"100494935","arterial-spin-labeling-mri-for-assessing-blood-perfusion-in-the-human-eye-repeatability-study-and-clinical-application-100494935","NCT05724641","Arterial Spin Labeling MRI for Assessing Blood Perfusion in the Human Eye Repeatability Study and Clinical Application","PerfRet","Inclusion criteria:\n\n* Carrier of target pathologies: TAO optic neuropathy, inflammatory optic neuropathy, ischemic optic neuropathy.\n* no cardiovascular risk factors or other ophthalmological pathology\n* adhere to the study protocol after reading the patient information document\n* signe the informed consent form to participate in the study\n* do not have any contraindications to an MRI examination\n\nExclusion criteria\n\n* Usual contraindications to MRI (Pacemaker, Metallic foreign body, Cochlear implant,…)\n* Severe claustrophobia",{"count":107,"type":22},[52],"The MRI perfusion imaging using arterial spin labeling (ASL)'s non-invasive technique (i.e. without injection of contrast medium) allows, thanks to recent technological improvement of the spatial resolution, measuring several perfusion parameter of the retinal tissue such as the regional Blood Flow (rBF) or the cerebral blood flow (cBF) expressed in ml\u002F100g\u002Fmin. Reliable application of ASL thus requires the precision and specificity of the MRI protocol to be tested.",[26],"2025-05-13",{"date":173,"type":33},"2025-05-16",{"date":175,"type":33},"2023-01-10",{"date":177,"type":22},"2026-06-30",{"name":179,"class":40},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":69},"100586642","an-interpretable-fundus-diseases-report-generating-system-based-on-weakly-labelings-100586642","NCT06918028","An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings","To Construct an Interpretable Multi-modal Report Generating System For Fundus Diseases Based On Weakly Labelings","Inclusion Criteria:\n\n* Disease group: All multimodal fundus examination images containing fundus lesions, examined from January 2011 to December 2023, including fundus photography, as well as OCT, OCTA, FFA, ICGA, B-ultrasound and corresponding imaging reports. Images could be either clear or unclear, reports are either complete or incomplete.\n* Normal group: All multimodal fundus examination images without fundus lesions, examined from January 2011 to December 2023, including fundus photography, as well as OCT, OCTA, FFA, ICGA, B-ultrasound and corresponding imaging reports. Images could be either clear or unclear, reports are either complete or incomplete.\n\nExclusion Criteria:\n\n* Disease group: 1. The image has serious quality problems; 2. The diagnostic report lacks key information.\n* Normal group: 1. The image has serious quality problems; 2. The diagnostic report lacks key information.",{"count":188,"type":22},9999,"To establish a multimodal fundus image report generation model to realize an interpretable system for multiple fundus diseases, multimodal image analysis, diagnosis, and treatment decision automatic reporting based on weakly labeled training data. Construct an interpretable feature fusion network for the clinical and imaging features of fundus lesions, and we hope to extract new imaging markers that can predict the occurrence and progression of various fundus lesions at an early stage, and ultimately verify them in real clinical data, further providing possible directions for exploring the molecular mechanisms of refractory fundus lesions, and may also provide new ideas for the precise prevention and treatment of fundus lesions.",[26,191,192,56,193,194],"Choroidal Disease","Pathological Myopia","Age Related Macular Degeneration","Choroidal Neovascularization","2025-04-05",{"date":197,"type":33},"2025-04-09",{"date":199,"type":22},"2025-05",{"date":201,"type":22},"2026-12",{"name":203,"class":40},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":18,"minAge":211,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":69},"100514703","real-world-of-ai-in-diagnosing-retinal-diseases-100514703","NCT05981950","Real-world of AI in Diagnosing Retinal Diseases","Real-world Application of Using Artificial Intelligence in Diagnosing Retinal Diseases","Inclusion Criteria:\n\n* fundus photography around 45° field which covers optic disc and macula\n* complete identification information\n\nExclusion Criteria:\n\n* insufficient information for diagnosis","1 Year","100 Years",{"count":214,"type":22},100000,"The objective of this study is to apply an artificial intelligence algorithm to diagnose multi-retinal diseases in real-world settings. The effectiveness and accuracy of this algorithm are evaluated by sensitivity, specificity, positive predictive value, negative predictive value, and area under curve.",[217,26],"Artificial Intelligence","2023-08-01",{"date":220,"type":33},"2023-08-08",{"date":218,"type":33},{"date":223,"type":22},"2029-08-01",{"name":225,"class":40},"Beijing Tongren Hospital"]